USP<665>塑料组件与系统通则生效,业内解读E&L风险框架与合规准备
USP 665《药品和生物制品原液和制剂生产使用的塑料组件和系统》已生效!
USP通则<665>已由资料性章节转为可执行章节,自2026年5月1日起适用于在美国生产或上市产品所用的一次性系统与多次使用系统,不覆盖传统路线化学合成的API及无实质接触的塑料辅助用品。
USP通则<665>已是已执行的强制性章节,在该通则出台之前,企业靠的是内部自建流程、供应商参差不齐的质量信息,以及行业指南的组合。新发布的USP<665>的适用于生产过程中使用的一次性系统(SUS)和多次使用系统(MUS)。如下:
USP General Chapter <665> Is Now Enforceable: Is Your E&L Program Ready?
USP通则<665>已执行:你的E&L体系准备好了吗?
Gowtham Nakka, Sakshi Gupta | BioProcess International | 4 November 2026
Gowtham Nakka、Sakshi Gupta|BioProcess International|2026年11月4日
With the compliance requirement now in effect, biopharmaceutical manufacturers face a mandatory, risk-based standard for evaluating plastic-component extractables and leachables.
合规要求现已生效,生物制药企业面对的,是一套用于评估塑料组件可提取物与浸出物(E&L)的强制性、基于风险的标准。
Modern pharmaceutical manufacturing relies heavily on plastics and polymer-based materials for equipment and processing supplies. Such materials include tubing, disposable bag bioreactors, filter housings, connectors, gaskets, mixing tanks, and many other components related to chromatography. In general, that type of equipment exposes plastic surfaces to a variety of process fluids, such as raw-material solutions, intermediate formulations, drug products (DPs), and final products. Wherever a liquid from one part of a process interacts with a piece of equipment made of plastic, there exists the potential for chemicals from the equipment to transfer into the process fluid. Those chemical substances coming from the equipment instead of from packaging and containers are referred to as process-equipment–related leachables (PERLs). Depending upon their identity and concentration level(s), PERLs can diminish product quality, stability, and efficacy/potency and therefore risk patient safety.
现代制药生产在设备与工艺耗材上高度依赖塑料和聚合物材料:管路、一次性袋式生物反应器、过滤器外壳、接头、垫圈、混合罐,以及许多与层析相关的部件。这类设备通常会让塑料表面接触各种工艺流体——物料溶液、中间品、制剂(DP)和最终产品。只要工艺中某处的液体与一件塑料设备发生接触,设备中的化学物质就有可能迁移进入工艺流体。这些来自设备而非来自包装容器的化学物质,称为工艺设备相关浸出物(PERLs)。视其种类和浓度水平,PERLs可能损害产品质量、稳定性与效价,进而危及患者安全。
To provide some consistency in risk evaluation, the United States Pharmacopeia (USP) has developed General Chapter <665>, "Plastic Components and Systems Used To Manufacture Pharmaceutical Drug Products and Biopharmaceutical Drug Substances and Products." Before the chapter’s development, companies had relied on a combination of internally developed processes, variable quality information from suppliers, and industrial guidance. Although useful in addressing the issue of potential contamination from plastic-component exposure, none provided the same degree of regulatory acceptance as a compendial standard. The lack of a standard complicated efforts to compare results obtained on similar plastic components, establish common expectations throughout the supply chain, and qualify acceptable alternatives.
为了让风险评估有一致的尺度,美国药典委员会(USP)制定了通则<665>《用于制造药品和生物制品的原液与制剂的塑料组件和系统》。在该通则出台之前,企业靠的是内部自建流程、供应商参差不齐的质量信息,以及行业指南的组合。这些做法虽有助于应对塑料组件接触带来的潜在污染问题,但没有任何一个能取得药典标准那样的监管接受度。缺乏标准,也让企业难以比较相似塑料组件上得到的检测结果、难以在供应链内建立统一预期、难以确认可接受的替代品。
The scope of <665> is limited to both single-use systems (SUS) and multiuse systems (MUS) utilized during manufacturing. Therefore, the chapter excludes the testing of chemically synthesized active pharmaceutical ingredients (APIs) produced via traditional routes and incidental plastic auxiliary items (e.g., scoops, funnels, pipettes, weighing dishes, and beakers) that do not have substantial or direct interaction with products. By focusing the testing efforts on the components/systems that truly represent a legitimate risk to product quality, <665> directs those efforts toward where they will have the most meaningful impact.
<665>的适用范围限于生产过程中使用的一次性系统(SUS)和多用途系统(MUS)。因此,该通则不要求检测以传统路线化学合成的原料药(API),也不覆盖与产品无实质或直接接触的偶发性塑料辅助用品(如药匙、漏斗、移液管、称量皿和烧杯)。把检测力气集中到真正对产品质量构成实际风险的组件/系统上——<665>让这些力气花在最有意义的地方。
The Compliance Timeline
合规时间线
General Chapter <665> has changed from an informational chapter into an applicable, enforceable one. As of 1 May 2026, compliance is expected for affected products that are manufactured or marketed in the United States; companies that have not stood up a program are carrying unresolved regulatory risk rather than preparing for some future deadline. In 2024, the committee approved General Chapter <665> together with its companion chapter, General Chapter <1665> on "Characterization and Qualification of Plastic Components and Systems Used to Manufacture Pharmaceutical Drug Products and Biopharmaceutical Drug Substances and Products." The companion chapter lays out the scientific rationale, risk-assessment logic, and worked details that support practical use of General Chapter <665>. Following approval, the committee extended the <665> effective date specifically to give the industry time to implement the requirements and to let the chapter track the development of a parallel international guideline.
通则<665>已经从资料性章节变成可适用、可执行的章节。自2026年5月1日起,在美国生产或上市的相关产品即被期待符合该通则;还没建立起E&L体系的公司,背着的是没有解决的监管风险,而不是在等一个未来的期限。2024年,专家委员会批准了通则<665>及其配套章节<1665>《用于制造药品和生物制品的原液与制剂的塑料组件和系统的表征与确认》。配套章节给出了科学依据、风险评估逻辑和落地细节,支撑<665>的实际执行。批准之后,委员会专门延长了<665>的生效日期,一是给行业留出落实要求的时间,二是让该章节与一份同步制定的国际指南保持同步。
The timeline does not end with <665>. General Chapter <661.2>, which addresses plastic packaging systems, became official on 1 December 2025. Revisions to the biological reactivity chapters <87> and <88> are scheduled to take effect on 1 December 2026. The American Society of Mechanical Engineers (ASME) is also expected to release an updated edition of its bioprocessing equipment (BPE) guidance in 2026. Anyone keeping current on the plastics landscape should treat these documents as an interconnected series of changes rather than isolated events because a single disposable assembly may fall under several of these chapters at once.
时间线并未止步于<665>。规范塑料包装系统的通则<661.2>已于2025年12月1日正式生效;生物反应性试验通则<87>与<88>的修订版定于2026年12月1日生效;美国机械工程师学会(ASME)预计也将在2026年发布其生物加工设备(BPE)指南的更新版。跟踪塑料法规动态的人,应当把这几份文件看成一串相互关联的变化,而不是孤立事件——因为同一个一次性组件,可能同时落进其中几份章节的管辖范围。
The Risk-Based Framework Behind <665> and <1665>
<665>与<1665>背后的基于风险的框架
The risk-based approach in General Chapter <665> will determine the extent of the testing required. Rather than requiring the completion of a complete and detailed analysis of all components, the scope of the investigation into potential hazards from PERLs will depend upon the likelihood that any single component would pose a hazard.
通则<665>采用基于风险的方法来决定检测要做到什么程度。它不要求对所有组件都做完整细致的分析,而是让针对PERLs潜在危害的调查范围,取决于单个组件构成危害的可能性。
There are two phases: An initial examination of each component and, when appropriate, a formalized risk assessment. The initial assessment uses a few simple questions regarding the component(s) being examined and how they are used.
评估分两个阶段:先对每个组件做初步审查,必要时再进行正式的风险评估。初步评估只问几个简单问题,围绕被审查组件及其使用方式:
· Are there process streams, biopharmaceutical drug substances (DSs), or DPs that come into contact with the component during its use?
· 该组件在使用过程中,是否会接触工艺流体、生物制品原液(DS)或制剂(DP)?
· Are there liquids involved with process streams, intermediates, DSs, or DPs with the component in question during its use?
· 该组件在使用中,是否有涉及工艺流体、中间品、DS或DP的液体与之接触?
· How does the component fit into a process system?
· 该组件在工艺系统中处于什么位置、如何接入?
· For how long and at what intensity is the component in contact with other parts of a process system?
· 该组件与工艺系统其他部件接触的时间和强度有多长、多大?
Documentation provided by vendors is important to support an initial assessment. In many cases, such documentation is identical in terms of that for material of construction, composition, and manufacturing method because another previously characterized component can eliminate additional testing requirements. At the conclusion of the initial assessment, only one question remains unanswered: Do tests need to be performed on this component?
供应商提供的文件对初步评估很重要。很多情况下,这类文件在材质、成分和制造方法上与另一个已有表征数据的组件完全相同——这时就可以引用既有数据,免除额外的检测。初步评估做完,只剩一个问题没有答案:这个组件需不需要做检测?
If testing needs to occur, then a risk assessment is conducted to identify the nature of such testing. An assessment of both individual and cumulative risks should be completed. Such assessments include leaching properties of the material, extraction conditions experienced by the material, proximity of the component to the finished product, and capabilities of subsequent processing activities to remove or dilute any extracts that may occur. In General Chapter <1665>, this type of activity is described as a systematic review of interactions involving each material that comes into contact with the product. Often that takes the form of a risk-evaluation matrix combining information regarding characteristics of the interaction as well as available data.
如果需要检测,就做风险评估来确定检测的性质。应当完成单项风险与累积风险两种评估,内容包括:材料的浸出特性、材料经历的提取条件、组件与成品的接近程度,以及后续工艺步骤清除或稀释可能浸出物的能力。在通则<1665>里,这类活动被描述为:对每一种与产品接触的材料所涉及的相互作用做系统审查。通常的做法是一张风险评估矩阵,把相互作用的特征信息与已有数据放在一起。
When chemical characterization is determined necessary, the primary focus of this effort is completing an extractables study under exaggerated, worst-case conditions using both aqueous and organic solvents to characterize all possible releases from the subject material. Techniques typically employed to analyze extracts include several orthogonal methods: headspace gas chromatography with mass spectrometry (GC-MS) for volatile compounds and semivolatiles, liquid chromatography with mass spectrometry (LC-MS) for polar and nonpolar species, and inductively coupled plasma mass spectrometry (ICP-MS) for elemental impurities. All results obtained through such analytical methods are evaluated against an analytical evaluation threshold (AET), which defines an acceptable level above which an individual extractable must be identified and further evaluated. Extractables exceeding established limits are subsequently subjected to a toxicological safety assessment. Provided that no toxicologically significant concerns exist relative to patient exposure, the resulting dataset provides sufficient information to support regulatory submissions. However, if issues arise, manufacturers have options including mitigating extractables’ impacts, replacing relevant components, or proceeding with targeted leachable studies conducted under realistic process-operating conditions and subsequent evaluation.
当判定有必要做化学表征时,这项工作的核心是在加严的最差条件下完成一项可提取物研究:用水性和有机两类溶剂,把目标材料所有可能的释放物表征出来。分析提取物常用的技术包括几种正交(互补)方法:顶空气相色谱-质谱(GC-MS)用于挥发性与半挥发性化合物,液相色谱-质谱(LC-MS)用于极性与非极性组分,电感耦合等离子体质谱(ICP-MS)用于元素杂质。所有检测结果都对照分析评价阈值(AET)评估——AET划定一个可接受水平,超过它的单个可提取物必须被鉴定并进一步评估。超出既定限度的可提取物,随后要做毒理学安全性评估。只要相对患者暴露不存在有毒理学意义的担忧,所得数据集就足以支持注册申报。如果出现问题,制造商仍有选择:减轻可提取物的影响、更换相关组件,或者在真实工艺运行条件下开展有针对性的浸出物研究并随后评估。
What Changes Now That the Chapter Is Mandatory?
通则变成强制要求之后,什么变了?
The transition from an information-based system to an application-based one is more than a minor shift in regulatory status. The previous system allowed companies to make reasonable arguments that their extractables and leachables (E&L) programs were based upon "good science," regardless of any published methodology; there was simply no applicable compendial chapter that required a specific approach. By contrast, now that General Chapter <665> is applicable, both inspectors and reviewers have a defined standard by which to evaluate programs; gaps will be considered findings as opposed to matters of professional judgment.
从资料性体系变成适用性体系,不只是监管身份的小改动。过去,企业可以理直气壮地说自己的E&L体系建立在"好的科学"之上,不管有没有公开的方法学——因为压根没有一部适用性药典章节要求你走特定路子。现在<665>已适用,检查员和审评员手里有了一把明确的尺子来衡量你的体系;缺口就是缺陷项,不再属于"专业判断"的余地。
From a practical standpoint, the burden of establishing suitability lies solely with the biomanufacturer and not the component supplier. Suppliers should develop extractable data and provide pertinent material information; however, it is the manufacturer’s duty to determine whether those data are sufficient to support its particular process and document that determination. No certification of compliance can legally transfer this burden of responsibility from the manufacturer.
从实务角度看,证明适用性的责任完全在生物制药企业,不在组件供应商。供应商应当提供可提取物数据和相关材料信息;但判断这些数据是否足以支持你的特定工艺、并把这一判断记录下来,是制造商的义务。任何合规证书都不能在法律上把这份责任从制造商身上转移出去。
Additionally, the chapter shifts how formal standards apply to the concept of industry best practices. The BioPhorum Operations Group (BPOG) extractables protocol remains an accepted reference point and incorporates many similar risk-management strategies; however, it is an industry-developed document and therefore represents best practice as opposed to a formally recognized compendial chapter. Therefore, now that General Chapter <665> has become applicable, manufacturers are expected to demonstrate clearly how their programs map to the requirements specified within General Chapter <665>, regardless of whether they continue to use study designs recommended in BPOG protocols as part of their testing. Demonstrating documentation of each decision made along with tracing these decisions back to their original premise will be the true measures of compliance.
此外,该通则改变了正式标准与"行业最佳实践"之间的关系。BioPhorum运营集团(BPOG)的可提取物研究方案仍是被认可的参考,也纳入了许多相似的风险管理策略;但它是一份行业自发制定的文件,代表的是最佳实践,而不是正式认可的药典章节。所以,如今<665>已经适用,无论你是否继续沿用BPOG方案推荐的研究设计作为检测的一部分,都被期待清楚地展示:你的体系如何映射到<665>规定的各项要求上。把每个决定记录在案、并能追溯回最初的前提——这才是合规真正的量尺。
Lastly, the new applicability converts compliance from a one-time qualification process into an ongoing life-cycle commitment. Manufacturers will need to revisit and update their risk assessments based on changes in their manufacturing processes, introduction of new single-use components, and so on, as well as new knowledge related to potential risks associated with leachables. A component that has been qualified under one set of processing conditions does not inherently qualify for use in a different product, over different contact times, or in a different location in a process.
最后,新的适用性把合规从一次性的确认流程,变成一项持续的生命周期承诺。工艺变更、引入新的一次性组件、以及关于浸出物潜在风险的新知识,都会要求制造商回头重新审视并更新风险评估。在某一组工艺条件下完成确认的组件,并不天然有资格用于另一个产品、不同的接触时间,或工艺中的另一个位置。
Fitting into the Broad Landscape of ICH Q3E and Biological Reactivity Chapters
置于ICH Q3E与生物反应性章节的大图景中
General Chapter <665> is being implemented at about the same time as an internationally coordinated effort to define a common method of evaluating E&L. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q3E draft guidance has recently received endorsement. ICH Q3E is intended to ensure safe use of drugs by patients and preserve product quality via a comprehensive and systematic approach to evaluate and manage leachable compounds using a risk-based strategy.
通则<665>落地的同时,一场定义E&L统一评估方法的国际协作也在推进。人用药品技术要求国际协调理事会(ICH)的Q3E指导原则草案最近已获得背书。ICH Q3E的目标是:用一套全面、系统、基于风险的策略来评估和管理浸出物,从而保障患者用药安全、守住产品质量。
The timing of the development of General Chapter <665> will coincide with the completion of ICH Q3E so that companies can reduce duplication associated with compliance requirements for products marketed worldwide. Currently, however, regulatory personnel must navigate a compendial chapter that requires compliance while waiting for a harmonized guideline to be developed and finalized after completion of public comment periods.
<665>的制定进度刻意与ICH Q3E的完成时点对齐,好让全球上市产品的企业减少合规要求上的重复劳动。但在眼下,监管事务人员还得先按一部已经要求合规的药典章节行事,同时等协调一致的指南走完公开征求意见程序、最终定稿。
A second dimension of change is related to biologic reactivity. Revisions to General Chapters <87> and <88>, effective on 1 December 2026, will expand the number of in vitro test methods available and changed the focus from the class VI plastics designations used historically to a focus on chemical characterization and in vitro biologic evaluation. Companies will require updates to specification documents, supplier documentation, and internal reference materials, including company publications that contain information referencing class VI classifications. Collectively, the above referenced changes clearly indicate an emerging trend away from general classification of raw materials based on broad categories to a specific process/product-focused and evidence-based approach.
第二维度的变化与生物反应性有关。2026年12月1日生效的通则<87>与<88>修订版,将增加可用的体外试验方法数量,并把重心从历史上使用的VI类塑料分级,转向化学表征与体外生物学评价。企业需要更新规格文件、供应商文件和内部参考资料,包括引用了VI类分级信息的企业出版物。综合来看,上述变化清楚地指出了一个正在成形的趋势:告别按大类对原材料做的笼统分级,走向针对具体工艺/产品、以证据为基础的方法。
Preparing for Compliance
为合规做准备
For quality and regulatory teams, process mapping starts with identifying each manufacturing system and component that contacts the process stream, intermediate, DS, or DP. The next step is to determine where each one fits in the process and under what conditions of contact it exists. Without an inventory of these components, there can be no defensible initial assessment.
对质量和注册团队来说,流程梳理从识别每一个接触工艺流体、中间品、DS或DP的生产系统和组件开始。下一步是确定每个组件在工艺中的位置,以及它处于什么样的接触条件。没有这份组件清单,就不可能有站得住脚的初步评估。
Following this step, supplier engagement must follow. Manufacturers need to collect extractables data, material-composition information, and change-notification commitments from suppliers and assess whether those data truly support equivalency or suitability conclusions. Commonly, gaps in supplier data exist and often require additional testing; they should be identified early to prevent a last-minute rush.
接下来是供应商沟通。制造商需要从供应商那里收集可提取物数据、材料成分信息和变更通知承诺,并评估这些数据是否真的足以支持等同性或适用性结论。供应商数据里有缺口是常态,往往需要补做检测;这些缺口要尽早识别,免得临近关头手忙脚乱。
Next, teams must formalize their risk-assessment methodology (ideally through a documented procedure), describing how the initial and risk assessments are conducted, how analytical evaluation thresholds are determined, and where toxicological assessments fit into that methodology. Using consistent written methodologies improves decision making and provides auditors with a clear trail of accountability now that the chapter has become enforceable.
再下一步,团队要把风险评估方法学正式成文(最好写成书面程序),说清楚初步评估和风险评估怎么做、分析评价阈值怎么定、毒理学评估在这个方法学里放在哪一环。章节已经可执行,一套一致的书面的方法学既能让决策更稳,也能给审计一个清晰的责任链条。
Documentation requires special attention. All decisions made during this process, including those based upon a scientific rationale that supports eschewal of testing for a given component or acceptance of an extractables profile as safe, must be retained in a form that would survive inspection. Organizations that run those activities electronically may want to consider building the workflow associated with meeting General Chapter <665> into electronic quality systems used for change control and periodic review so that the life-cycle obligation is met instead of forgotten once qualification is complete.
文件记录要特别注意。这个过程中的所有决定——包括基于科学依据而不对某组件做检测的决定、或接受某可提取物谱为安全的决定——都必须以经得起检查的形式留存。以电子方式运行这些活动的组织,可以考虑把满足<665>的工作流建进变更控制和定期评审所用的电子质量系统里,让生命周期义务被履行,而不是在确认完成后被遗忘。
Lastly, teams should plan to address changes adjacent to General Chapter <665> instead of treating them independently. Because General Chapters <87> and <88> and ICH Q3E are landing at overlapping timelines, a single coordinated program that addresses chemical characterization, biological reactivity, and harmonized safety assessment issues will be far less burdensome than three separate projects. Many other activities related to training suppliers and updating specifications can also be handled within a single project.
最后,团队应当把<665>周边的变化放在一起统筹,而不是各自为战。<87>、<88>和ICH Q3E的落地时间相互重叠,用一个统筹的项目同时应对化学表征、生物反应性与协调后的安全性评估,远比拆成三个项目轻松。培训供应商、更新规格等许多其他工作,也都可以放进同一个项目里。
What’s the Bottom Line?
底线是什么?
General Chapter <665> represents a significant advancement in terms of how the pharmaceutical industry will be able to assess and manage the risks associated with manufacturing plastics in relation to product quality and patient safety. In doing so, it establishes a risk-based standard for all parties who have to evaluate the potential for PERL migration into DPs; this is established based upon the scientific detail contained within General Chapter <1665>. The establishment of <665>, along with the new biological reactivity standards and emerging ICH Q3E guidelines, further demonstrates a trend toward reliance on product- and process-specific data rather than general classification of materials. For most manufacturers, the message is straightforward: Develop and document your life-cycle–based E&L program now, base your documentation on a defensible risk assessment, and integrate your program development efforts with other upcoming initiatives in this area. An organization’s ability to apply a consistent risk-management approach to E&L, rather than viewing it as a one-time barrier to entry, will be rewarded under General Chapter <665>.
通则<665>是一个重大进步:制药业从此有了一套办法,来评估和管理生产用塑料对产品质量与患者安全的风险。它为所有需要评估PERL迁移进入制剂之可能性的各方,确立了一套基于风险的标准,其科学细节以通则<1665>的内容为基础。<665>的确立,连同新的生物反应性标准和正在成形的ICH Q3E指南,进一步印证了这个趋势:依靠产品和工艺的专属数据,而不是材料的笼统分级。对多数制造商来说,话说得很直白:现在就建立并以文件落实你基于生命周期的E&L体系,把文件建立在站得住脚的风险评估之上,并把这项工作与该领域其他即将到来的举措整合起来。谁能把一套一致的风险管理方法用在E&L上,而不是把它当成一次性的入场关卡,谁就会在通则<665>之下得到回报。
来源:制药经理人 · mp.weixin.qq.com